The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts

Wiktor, Stefan Z.; Hutin, Yvan

doi:10.1016/s0140-6736(16)31018-2

Cited by 52 publications

(42 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Implementation of universal infant vaccinations and catch‐up vaccinations in children and high‐risk individuals has dramatically decreased the number of people susceptible to HBV infection. However, chronic hepatitis B infection remains one of the major liver diseases that lead to cirrhosis and HCC . Our study suggests that the prevalence of hepatitis B infection, past exposure and immunity pattern varies among racial groups.…”

Section: Discussionmentioning

confidence: 69%

“…Of the 14 720 persons, the overall prevalence of vaccine-induced Table 4). All races except Hispanics showed the highest prevalence in the age group 20 Of these individuals, only 40.0% had detectable protective HBsAb level (>10 IU/L), and 0.2% were found to be chronically infected with HBV. Additionally, 23.9% of those who did not know about their immunization history (10.4% of all participants) had detectable protective antibody titres.…”

Section: Hbv Vaccine-induced Immunity (Hbsab+ Anti-hbc-)mentioning

confidence: 96%

See 1 more Smart Citation

Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States

Kim

Rotundo

Yang

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection in the US is the most common among Asians followed by non-Hispanic blacks. However, there have been few studies that describe HBV infection and immunity by racial group. Our study aims to assess racial/ethnic disparities in the prevalence and awareness of HBV infection and immunity using nationally representative data. In the National Health and Nutrition Examination Survey 2011–2014, 14,722 persons had HBV serology testing. We estimated the prevalence of HBV infection, past exposure, and immunity by selected characteristics and calculated adjusted odds ratios using survey-weighted generalized logistic regression. Awareness of infection and vaccination history was also investigated. The overall prevalence of chronic HBV infection, past exposure, and vaccine-induced immunity was 0.34% [95%CI 0.24–0.43], 4.30% [95%CI 3.80–4.81], and 24.4% [95%CI 23.4–25.4], respectively. The prevalence of chronic infection was 2.74% [95% CI 1.72–3.76] in Asians, 0.64% [95% CI 0.35–0.92] in non-Hispanic blacks, and 0.15% [95% CI 0.06–0.24] in non-Asian, non-blacks. Only 26.2% of those with chronic infection were aware of their infection. The prevalence of the past exposure was 21.5% [95%CI 19.3–23.7] in Asians, 8.92% [95%CI 7.84–9.99] in non-Hispanic blacks, 2.05% [95%CI 1.49–2.63] in non-Hispanic whites, and 4.47% [95%CI 3.25–5.70] in Hispanics. Prevalence of vaccine-induced immunity by each race was 34.1% [95%CI: 32.0–36.2] in Asians, 25.5% [95%CI: 24.0–27.0] in non-Hispanic blacks, 24.0% [95%CI: 22.6–25.4] in non-Hispanic whites, and 22.2% [95%CI: 21.3–23.3] in Hispanics. There are considerable racial/ethnic disparities in HBV infection, exposure, and immunity. More active and sophisticated healthcare policies on HBV management may be warranted.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Hbv Vaccine-induced Immunity (Hbsab+ Anti-hbc-)mentioning

confidence: 96%

Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States

Kim

Rotundo

Yang

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…[2][3][4] With the emergence of effective direct-acting antiviral treatments for HCV, policies to address the HCV disease burden at the national and global levels will require the use of more accurate epidemiological data. 5 There remains, however, a lack of robust data on HCV-and liver-related mortality at the country level, as well as significant heterogeneity in pooled global estimates. 6 It was recently estimated that globally 71 million people have active viremic HCV infections.…”

Section: Introductionmentioning

confidence: 99%

The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4

Chan

Chen

Omede

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

“…Global morbidity has also increased in terms of years lived with disability from 0.65 million to 0.87 million and Disability-Adjusted Life-Years (DALY) from 31.7 million to 42.5 million. 18 Review of literature by Umer et al published in 2016, summarized 13 studies of seroprevalence of HCV infection in blood donors from various areas in Pakistan during the period of 2009 to 2014 encompassing a total of 403,436 blood donors. 19 The reported prevalence ranged from 1.65% to 20.8%.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of hepatitis C virus among healthy donors at a large Teaching Hospital in Lahore, Pakistan: A cause of concern for health policy makers.

Hameed

Abdullah

Ali

et al. 2019

TPMJ

View full text Add to dashboard Cite

Objectives: Hepatitis C Virus (HCV) infection is life threatening but with the advent of new antiviral agents is potentially curable. Its prevalence among healthy blood donors was estimated in Mayo Hospital, Lahore, Pakistan. The aim of this study was to help in estimating disease burden in addition to early diagnosis of asymptomatic individuals necessitating treatment. Study Design: Retrospective single centre cross-sectional study. Setting: Mayo Hospital, Lahore, Pakistan. Period: January 2016 to December 2017. Material and Methods: Blood donors were tested for Anti-HCV antibodies by qualitative test based on lateral flow immunoassay using commercially made rapid test kits. Results: In 2016 and 2017, a total of 76530 healthy blood donors were screened for anti-HCV antibodies. Out of 76530 donors, 2095 were found to have anti-HCV antibodies constituting cumulative percentage of 2.73%. The seroprevalence was 2.49% in 2016 and reached to 2.97% in 2017. Conclusion: Sero-prevalence of Hepatitis C among healthy blood donors is quite high at 2.73% and has slightly increased in 2017 compared to 2016. This dictates need for continued community awareness for prevention, early detection, and treatment. This study will be helpful for health policy makers to design more effective strategic planning to eradicate Hepatitis C infection.

show abstract

The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts

Cited by 52 publications

References 4 publications

Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States

Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States

The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4

Prevalence of hepatitis C virus among healthy donors at a large Teaching Hospital in Lahore, Pakistan: A cause of concern for health policy makers.

Contact Info

Product

Resources

About